Bradley Canino
Stock Analyst at Guggenheim
(4.54)
# 1,035
Out of 4,835 analysts
290
Total ratings
49.6%
Success rate
13.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintained: Buy | $135 → $170 | $118.15 | +43.88% | 22 | Aug 31, 2026 | |
| CELC Celcuity | Rated: Buy | $165 → $175 | $88.44 | +97.87% | 16 | Aug 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $58 → $55 | $18.03 | +205.05% | 10 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $13.24 | +35.95% | 11 | Aug 3, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $13.73 | +176.77% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $5.58 | +61.29% | 1 | Jul 19, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $31 | $19.54 | +58.65% | 18 | Jul 14, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $40 | $29.00 | +37.93% | 5 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $10.27 | +240.80% | 5 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $23.43 | +79.26% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $26 | $18.77 | +38.52% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $17.75 | +97.18% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $24.94 | +116.52% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $21.70 | +38.25% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $74.34 | +21.07% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.85 | +81.82% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.23 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $12.66 | n/a | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $3.23 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.80 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $2.00 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $9.18 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $4.13 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $57.80 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $16.30 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $1.74 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.34 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $54.45 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $28.27 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $34.07 | n/a | 1 | Jul 8, 2020 |
Kymera Therapeutics
Aug 31, 2026
Maintained: Buy
Price Target: $135 → $170
Current: $118.15
Upside: +43.88%
Celcuity
Aug 16, 2026
Rated: Buy
Price Target: $165 → $175
Current: $88.44
Upside: +97.87%
Janux Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $58 → $55
Current: $18.03
Upside: +205.05%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $13.24
Upside: +35.95%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $13.73
Upside: +176.77%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $5.58
Upside: +61.29%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $31
Current: $19.54
Upside: +58.65%
Damora Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $29.00
Upside: +37.93%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $10.27
Upside: +240.80%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $23.43
Upside: +79.26%
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $18.77
Upside: +38.52%
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $17.75
Upside: +97.18%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $24.94
Upside: +116.52%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $21.70
Upside: +38.25%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $74.34
Upside: +21.07%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.85
Upside: +81.82%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $2.23
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $12.66
Upside: n/a
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $3.23
Upside: n/a
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $3.80
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $2.00
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $9.18
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $4.13
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $57.80
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $16.30
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $1.74
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.34
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $54.45
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $28.27
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $34.07
Upside: n/a